about
Short-term follow-up of chagasic patients after benzonidazole treatment using multiple serological markers.Differential phenotypic and functional profiles of TcCA-2 -specific cytotoxic CD8+ T cells in the asymptomatic versus cardiac phase in Chagasic patients.Characterization of an immunodominant antigenic epitope from Trypanosoma cruzi as a biomarker of chronic Chagas' disease pathology.Guidelines on the treatment of chronic coinfection by Trypanosoma cruzi and HIV outside endemic areas.A 12-mer repetitive antigenic epitope from Trypanosoma cruzi is a potential marker of therapeutic efficacy in chronic Chagas' disease.The innate immune response status correlates with a divergent clinical course in congenital Chagas disease of twins born in a non-endemic country.Success of benznidazole chemotherapy in chronic Trypanosoma cruzi-infected patients with a sustained negative PCR result.Risk factors and primary prevention of congenital Chagas disease in a nonendemic country.Trypanosoma cruzi paraflagellar rod proteins 2 and 3 contain immunodominant CD8(+) T-cell epitopes that are recognized by cytotoxic T cells from Chagas disease patients.Antiparasitic Treatment Induces an Improved CD8+ T Cell Response in Chronic Chagasic Patients.[Diagnosis and treatment of Chagas disease].[Eosinophilia and a subcutaneous nodule in patient from Equatorial Guinea].Identification of HLA-A∗02:01-restricted CTL epitopes in Trypanosoma cruzi heat shock protein-70 recognized by Chagas disease patients.Nifurtimox chemotherapy: collateral effects in treated Trypanosoma cruzi infected patientsLimitations of currently available Chagas disease chemotherapy[Congenital Chagas disease in a newborn of a Bolivian mother][Ancylostomiasis: a potential cause of iron deficiency anemia in patients from endemic areas]
P50
Q33975717-572CA5BA-A74B-4179-AEBD-787E97713C16Q35588670-0D76C9D5-C469-4699-89C9-9F224AE21F0FQ35739066-95CE92A7-CD24-433E-8FD9-61936B76DF92Q37970541-A0834AC8-3F21-445C-B386-F4B44CCFA16CQ39002789-A24EC83B-55F3-4252-8E90-69B4BA93AF7FQ39003067-27904984-AD23-4839-A4DB-2601DF4B68EDQ39282269-3632FB0D-B522-4D9E-A998-3B9E9A5A04CBQ39282275-68749CAF-F413-4738-8506-B15BA416C4FDQ39322119-5E420BA2-33C8-4CC8-B1AA-B4084540C1AEQ40309242-03AC0078-F368-4B1D-9DA1-64E8C6A0942CQ43613486-53E2FFF7-CC75-46E1-BB88-8ADA0FD81EDBQ46846289-CB47F86E-880A-4D87-AE80-42F20386AF32Q51554216-C1BB074E-34BF-498E-8D5A-9408278774B5Q58843566-D294633F-09F6-49DF-B0C7-AAFD7A3317FBQ58843568-3CEABDE7-F5C3-43C7-85E9-4C916DEB6186Q58844290-4C9E3D1B-BC62-45DD-ADC9-9D7670CB31A9Q84277026-54F24733-C3F0-4CAB-86A5-CB5185AB5745
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Bartolomé Carrilero
@en
Bartolomé Carrilero
@nl
type
label
Bartolomé Carrilero
@en
Bartolomé Carrilero
@nl
prefLabel
Bartolomé Carrilero
@en
Bartolomé Carrilero
@nl
P31
P496
0000-0002-0110-603X